Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer’s disease and dementia with Lewy bodies from the prodromal stage

被引：0

作者：

Olivier Bousiges

Nathalie Philippi

Thomas Lavaux

Armand Perret-Liaudet

Ingolf Lachmann

Caroline Schaeffer-Agalède

Pierre Anthony

Anne Botzung

Lucie Rauch

Barbara Jung

Paulo Loureiro de Sousa

Catherine Demuynck

Catherine Martin-Hunyadi

Benjamin Cretin

Frédéric Blanc

机构：

[1] University Hospital of Strasbourg,Laboratory of Biochemistry and Molecular Biology

[2] University of Strasbourg,Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA)

[3] CNRS UMR7364,CM2R (Research and Resources Memory Centre), Geriatric Day Hospital and Neuropsychology Unit, Geriatrics Department

[4] University Hospitals of Strasbourg,Neurochemistry Laboratory, Biochemistry Department, Centre de Biologie et Pathologie Est

[5] University of Strasbourg and CNRS,BIORAN Team, Lyon Neuroscience Research Center, CNRS UMR 5292

[6] ICube Laboratory UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), INSERM U1028

[7] Team IMIS,Center for Memory Resources and Research, Hospices Civils de Lyon

[8] Hospices Civils de Lyon,Geriatrics Department

[9] Université de Lyon - Université Claude Bernard,undefined

[10] Charpennes Hospital,undefined

[11] Lyon 1 University,undefined

[12] AJ Roboscreen GmbH,undefined

[13] General Hospital Centre,undefined

[14] CM2R,undefined

[15] Geriatric Day Hospital,undefined

来源：

Alzheimer's Research & Therapy | / 12卷

关键词：

Dementia with Lewy bodies; Alzheimer’s disease; Prodromal; Dementia; Cerebrospinal fluid biomarkers; Total alpha-synuclein;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 271 条

[1]

McKeith IG(1996)Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop Neurology. 47 1113-1124

[2]

Galasko D(2000)Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies Neurology. 54 1050-1058

[3]

Kosaka K(2005)Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology. 65 1863-1872

[4]

Perry EK(2017)Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium Neurology. 89 88-100

[5]

Dickson DW(2010)Low sensitivity in clinical diagnoses of dementia with Lewy bodies J Neurol 257 359-366

[6]

Hansen LA(2020)Research criteria for the diagnosis of prodromal dementia with Lewy bodies Neurology. 94 743-755

[7]

McKeith IG(2011)Prevalence and pathology of dementia with Lewy bodies in the oldest old: a comparison with other dementing disorders Dement Geriatr Cogn Disord 31 309-316

[8]

Ballard CG(2019)Diagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies Clin Chim Acta 490 222-228

[9]

Perry RH(2016)Diagnostic value of cerebrospinal fluid biomarkers (phospho-Tau181, total-tau, Abeta42, and Abeta40) in prodromal stage of Alzheimer’s disease and dementia with Lewy bodies J Alzheimers Dis 51 1069-1083

[10]

Ince PG(2018)Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage J Neurol Neurosurg Psychiatry 89 467-475

← 1 2 3 4 5 6 7 8 9 10 →